Drug resistance and treatment failure in leishmaniasis: A 21st century challenge

A Ponte-Sucre, F Gamarro, JC Dujardin… - PLoS neglected …, 2017 - journals.plos.org
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …

Medicinal attributes of 1, 2, 3-triazoles: Current developments

D Dheer, V Singh, R Shankar - Bioorganic Chemistry, 2017 - Elsevier
Triazoles are important five-membered heterocyclic scaffold due to their extensive biological
activities. This framework can be readily obtained in good to excellent yields on the …

Recent advances and new strategies on leishmaniasis treatment

BM Roatt, JM de Oliveira Cardoso… - Applied Microbiology …, 2020 - Springer
Leishmaniasis is one of the most important tropical neglected diseases according to the
World Health Organization. Even after more than a century, we still have few drugs for the …

Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …

N Aronson, BL Herwaldt, M Libman… - Clinical infectious …, 2016 - academic.oup.com
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

[图书][B] World health report 2013: Research for universal health coverage

World Health Organization - 2013 - apps.who.int
، ﺎﺑ 砠 ᖠﺳ ﻮﻜﺴﻴﺴﻧاﺮﻓ يد ﺲﻳﻮﻟ، رﺎﻣﻮﻛ ﺔﺸﺋﺎﻋ، ﺰﻠﺳﺎﻛ ورﺪﻧأ، مرﺪﻨﻟ–ﻞﺒﻣﺎﻛ ﺪﻴﻣرﺎﻳد، ﺘﻴﺑ سﻼ ود، د 砠 ᖠﻴﺑ نﻮﺟ، ﻲﺠﺑرﻮﺸﻟا
ﺐﻴﺠﻧ، بﻮﺴﻟا ينﻟورﺎﻛ ﺎﻧﺎﺘﻳﻮ ﰲﻮﺻ، رﻮﺒﺴﻜﻴﻳﺮ ﻪﻳرﺪﻧآ، ﻮﻟﻮ غارﻻ، رﺎﻔﻐﻟا ﺪﺒﻋ، نﻮﻫﺎﺘﻴ سﻮﺴﻴﻴﻠﻳﺎﻫ، ﻚﻴﻠﻓ ﺎﻧﻮﻴﻓ، ﻴﻓ ﻲﺘﺴﻳﺮﻛ …

Visceral leishmaniasis: recent advances in diagnostics and treatment regimens

J van Griensven, E Diro - Infectious Disease Clinics, 2019 - id.theclinics.com
Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by Leishmania
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize …

Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives

F Alves, G Bilbe, S Blesson, V Goyal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Research in visceral leishmaniasis in the last decade has been focused on how better to
use the existing medicines as monotherapy or in combination. Systematic research by …

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis

AS Nagle, S Khare, AB Kumar, F Supek… - Chemical …, 2014 - ACS Publications
Leishmaniasis is a parasitic disease that presents four main clinical syndromes: cutaneous
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral leishmaniasis/kala azar …

An update on pharmacotherapy for leishmaniasis

S Sundar, J Chakravarty - Expert opinion on pharmacotherapy, 2015 - Taylor & Francis
Introduction: Leishmaniasis broadly manifests as visceral leishmaniasis (VL), cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis. The treatment of leishmaniasis is …

Chemotherapy of leishmaniasis: present challenges

SRB Uliana, CT Trinconi, AC Coelho - Parasitology, 2018 - cambridge.org
Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …